USAID Support Makes Cutting-Edge HIV Drug Available in Vietnam in Record Time

Friday, January 3, 2020

In July 2019, the World Health Organization (WHO) recommended a fixed dose combination of Tenofovir–Lamivudine–Dolutegravir (TLD) to treat HIV/AIDS as it is more effective and has fewer side effects, which results in fewer patients dropping out of treatment. Thanks to advocacy efforts by USAID and other partners, Vietnam’s Ministry of Health granted a Marketing Authorization for TLD in October, allowing PEPFAR and the Global Fund to immediately start a small number of patients on TLD. In December, Vietnam reached a critical milestone when the first two PEPFAR-funded TLD shipments arrived in-country after nine weeks and received respective customs/duty waiver clearances, compared with a six-month ordering period. USAID’s Global Health Supply Chain, Procurement and Supply Management (GHSC/PSM) project drove this accelerated process by pushing the manufacturer, Mylan, to get Vietnam's order produced, shipped and imported, even with Vietnam’s specific marking specifications, and helping Vietnam’s Ministry of Health push all the customs paperwork through in record time.

So What? The expedited lead time makes this superior HIV treatment regimen available to people living with HIV/AIDS in Vietnam from December 2019, paving the way for Vietnam’s Social Health Insurance to procure TLD for distribution in 2021 to a majority of the country’s HIV patients on treatment. 

Last updated: February 21, 2020

Share This Page